Sjögren's disease
SjD · Immunology · 3 drugs · 2 indications
Competitive Landscape (3 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Ianalumab | NVS | BAFF receptor antagonist | Antibody | SC | PHASE3 |
| Dazodalibep | AMGN | CD40 ligand inhibitor | VHH domain antibody | SC | PHASE3 |
| VOYXACT | 4578 | Anti-APRIL Monoclonal Antibody | Monoclonal antibody | SC | APPROVED |
Indications (2)
Upcoming Catalysts
VOYXACT - IgA Nephropathy - Ph3 - eGFR Confirmatory Data (VISIONARY)CLINICAL
4578Early 2026
Dazodalibep - Sjogren's - Ph3 Data (2 studies)CLINICAL
AMGN2026
Ianalumab - SLE - Ph3 - Topline (SIRIUS-SLE)CLINICAL
NVSH2 2026
Ianalumab - Sjogren's - Ph3 - ToplineCLINICAL
NVS2027
Data from Supabase · Updated 2026-03-24